Case Report: Two cases of chemotherapy refractory aggressive variant prostate cancer with extreme durable response to PARP inhibitor
These two cases demonstrating a satisfactorily durable response to PARP inhibitors indicating its clinical benefit in AVPC population with detected DNA damage response (DDR) defects. The survival improvement with PARP inhibitors observed in our clinical experiences, along with current advances in tumor sequencing provide more information on future clinical trials and explorations of innovative therapies in AVPC population.
Authors
- Jianbin Bi (ORCID: https://orcid.org/0000-0002-7703-4765)
- Gejun Zhang (ORCID: https://orcid.org/0000-0003-3482-5468)
- Yiming Chen (ORCID: https://orcid.org/0000-0002-7165-8518)
- Y.J Bi (ORCID: https://orcid.org/0000-0001-6255-2191)
- Jian Deng (ORCID: https://orcid.org/0000-0001-9442-0820)
- Bohao Jiang (ORCID: https://orcid.org/0009-0004-7785-5792)
Institutions
- Shenyang Fifth People Hospital (CN)
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fonc.2025.1533627
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52